Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Oncological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ERVWE1/ERVW-1 (Syncytin-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERVWE1/ERVW-1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed (native glycosylation). Sequence Verified. |
View ERVWE1/ERVW-1 Products |
| Gene Delivery | ERVWE1/ERVW-1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter, puromycin selection. |
View ERVWE1/ERVW-1 Products |
| Benchmark Ab | Anti-ERVWE1/ERVW-1 (Sequence of Temelimab/GNbAC1 Reference) Recombinant positive control targeting fusion peptide. Sequence Verified. |
View ERVWE1/ERVW-1 Products |
| Validator | ERVWE1/ERVW-1 siRNA Set (3 unique clones) For knockdown verification in cell fusion assays. |
View ERVWE1/ERVW-1 Products |
| Related Target: SLC1A4 | ASCT1 – Primary receptor mediating fusogenic activity in CNS. | View SLC1A4 Products |
| Related Target: SLC1A5 | ASCT2 – Secondary receptor, primary entry receptor for ERVWE1, also crucial in tumor metabolism. | View SLC1A5 Products |
| Related Target: ERVFRD-1 | Syncytin-2 (HERV-FRD) – Critical counter-target for cross-reactivity screening. High homology family member. | View ERVFRD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Binding Neutralization | HEK293 Expressed (Native Glycosylation) ECD ensures accurate ASCT1/2 interaction profiles. |
| Functional Syncytium Formation Assay | Lentivirus for Stable Cell Line generation to evaluate real-time cell fusion inhibition. |
| Viral Envelope Glycosylation Fidelity | HEK293 Expression System preserves mammalian N-glycosylation patterns critical for neutralizing epitope presentation. Purity >95% by SDS-PAGE. |
| Syncytin-2 (HERV-FRD) Cross-Reactivity | Strict Sequence Verification against ERVFRD-1 isoforms ensures antigen specificity. Distinct immunogen design available. |
| ASCT2-Mediated Fusion Assay | Lentivirus particles for stable ERVWE1 expression in target cells (BeWo/SH-SY5Y). Preserves native conformation for entry studies. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Flow Cytometry | Validated siRNA included for specificity checks and target validation. |
Live ERVWE1/ERVW-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ View Active Clinical Trials (MS)
Global Clinical Landscape & Future Outlook
The race for ERVWE1/ERVW-1 (Syncytin-1) therapeutics is intensifying around the “viral etiology” hypothesis of neurodegeneration. GeNeuro’s GNbAC1 (anti-Syncytin‑1) leads in Phase 3 for Multiple Sclerosis (MS) and Phase 2 for ALS, representing the first-in-class approach to neutralize endogenous retroviral envelope proteins. Originally recognized for its physiological role in placentation, pathological expression of Syncytin-1 is now strongly linked to neuroinflammation (Multiple Sclerosis) and various cancers. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination therapies with B-cell depleting agents, enhanced blood-brain barrier (BBB) penetrance, and refined epitope mapping to distinguish pathological from physiological fusogenic activity.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Neutralizing) | GeNeuro (GNbAC1) | Multiple Sclerosis, ALS, Long COVID | Cell Fusion Inhibition Assay (Requires full-length Lentivirus for native conformation) |
| Bispecifics | Early-stage biotechs | Solid Tumors | Receptor Blocking Validation (Need precise ASCT1/ASCT2 binding models) |
| Decoy Receptor | Academic Consortia | Neuroinflammation | High-Affinity SPR Validation (Need pure ECD-Fc with correct glycosylation) |
| Small Molecule | Academic Consortia / Early Discovery | Neuromuscular Diseases, Trophoblastic Disease | Selectivity Assay (Need structural fidelity via Sequence Verified proteins) |